Investor consortium sells Sirigen to BD

The investors have enjoyed returns in the 2.5-4x range on their original investments. The acquisition will allow BD to expand its life sciences research reagent portfolio.

Previous funding
In 2008, Seraphim Capital led a £2m round for Sirigen, alongside Oxford Capital Partners. The following year, both investors provided the company with a further £1.2m.

In 2010, a consortium of investors injected £3.83m into Sirigen. The round was led by IQ Capital, Nesta and YFM. Existing investors Seraphim and Oxford Capital Partners also contributed.

A year later, YFM led a $3m investment in the firm. The capital was provided through the Seraphim Capital Fund and British Smaller Companies VCT 2. Other investors included Oxford Capital Partners, IQ Capital and Nesta.

Company
Founded in 2003 and based in Ringwood, Hampshire, Sirigen is a global medical technology company that produces light harvesting polymers with a range of applications in research, medical diagnostics and life sciences.

The firm has offices in San Diego, California, and Ringwood. It employs 15 members of staff.

People
Kit Hunter Gordon is chairman of Seraphim. David Mott is an investment director at Oxford Capital Partners. Ivan Griffin is an investment director at Nesta. David Bell is a director at YFM. David Evans joined Sirigen as chairman in 2010 as part of the investment round.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Exits
• United Kingdom
• Seraphim Capital
• YFM Group